{"id":"rchop21","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Infection"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rituximab is a monoclonal antibody that binds to the CD20 antigen on B cells, leading to their depletion. Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death. Doxorubicin is an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and inducing apoptosis. Prednisone is a corticosteroid that suppresses the immune system and inhibits inflammation.","oneSentence":"Rituximab targets and depletes CD20-positive B cells, while cyclophosphamide, doxorubicin, and prednisone work through various mechanisms to induce cell death in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:28.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Follicular lymphoma"},{"name":"Diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06813573","phase":"NA","title":"Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-09-30","conditions":"Follicular Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":50},{"nctId":"NCT01285765","phase":"PHASE3","title":"Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2010-12","conditions":"DLBCL","enrollment":650},{"nctId":"NCT00644124","phase":"PHASE1","title":"Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-03","conditions":"Lymphoma, Non-Hodgkin","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rituximab-CHOP21"],"phase":"phase_3","status":"active","brandName":"RCHOP21","genericName":"RCHOP21","companyName":"The Lymphoma Academic Research Organisation","companyId":"the-lymphoma-academic-research-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab targets and depletes CD20-positive B cells, while cyclophosphamide, doxorubicin, and prednisone work through various mechanisms to induce cell death in cancer cells. Used for Follicular lymphoma, Diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}